NCT01194284

Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

Observational, Noninterventional Surveillance Study of Patients With Newly Diagnosed Osteosarcoma

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 25 (actual)
• Sponsor: Millennium Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 2 Years – 40 Years
• Healthy volunteers: Not accepted

Summary

This study is an observational safety surveillance study designed to prospectively assess patients with high-grade osteosarcoma who are candidates for treatment with mifamurtide within the context of prevailing standard oncology practice

Conditions

• Osteosarcoma

Interventions

Type	Name	Description
DRUG	Mifamurtide	Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.

Timeline

• Start date: 2011-12-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2010-09-02
• Last updated: 2017-01-19

Locations

1 site across 1 country: Austria